Her-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients

Journal of Clinical Gastroenterology

Volumn 46, Issue 4, 2012, Pages e31-e37

  Liu, Wei ^a   Zhong, Shan ^a   Chen, Juan ^a   Yu, Yinghao ^a  

^a Dongfang Hospital   (China)

Author keywords

Fluorescence in situ hybridization; Gastric cancer; HER 2 neu; Immunohistochemistry; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 84858861957     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31823457ea     Document Type: Article

References (44)

1. Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors. J Clin Epidemiol. 2003;56:1-9
2. Ross JS, Fletcher JA, Hortobagyi GN, et al. HER-2/neu testing in breast cancer. Am J Clin Pathol. 2003;120(suppl):S53-S71
3. Coussens L, Yang-Feng TL, Francke U, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 1985;230:1132-1139
4. Ross JS, Fletcher JA, Hortobagyi GN, et al. Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics. 2004;3:379-798
5. Hung MC, Lau YK. Basic science of HER2 /neu: a review. Semin Oncol. 1999;4(suppl 12):51-59
6. Press MF, Slamon DJ, Bernstein L, et al. Evaluation of HER-2/neu gene amplification and overexpression. J Clin Oncol. 2002;20:3095-3105
7. Slamon DJ, Godolphin W, Ullrich A, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707-712
8. Ménard S, Casalini P, Tagliabue E, et al. HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer. Ann Oncol. 2001;12(suppl 1):15-19
9. Smith I, Procter M, Dowsett M, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007;369:29-36
10. Slamon DJ, Leyland-Jones B, Norton L, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792
11. Jørgensen JT. Targeted HER2 treatment in advanced gastric cancer. Oncology. 2010;78:26-33
12. Croxtall JD, McKeage K. Trastuzumab: in HER2-positive metastatic gastric cancer. Drugs. 2010;70:2259-2267
13. Tateishi M, Toda T, Nagasaki S, et al. Clinicopathological significance of c-erbB-2 protein expression in human gastric carcinoma. Surg Oncol. 1992;49:209-212
14. Sasano H, Date F, Nagura H, et al. Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells. Hum Pathol. 1993;24:584-589
15. Uchino S, Tsuda H, Hirohashi S, et al. Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients. Cancer. 1993;72:3179-3184
16. Mizutani T, Onda M, Sugisaki Y, et al. Relationship of c-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer. Cancer. 1993;72:2083-2088
17. Ooi A, Kobayashi M, Nakanishi I, et al. Amplification of c-erbB-2 in gastric cancer: detection in formalin-fixed, paraffin-embedded tissue by fluorescence in situ hybridization. Lab Invest. 1998;78:345-351
18. Sato T, Abe K, Kurose A, et al. Amplification of the c-erbB-2 gene detected by FISH in gastric cancers. Pathol Int. 1997;47:179-182
19. Sobin LH, Fleming ID. TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer. 1997;80:1803-1804
20. Hofmann M, Stoss O, Henkel T, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52:797-805
21. Pauletti G, Dandekar S, Slamon DJ, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000;18:3651-3664
22. Takehana T, Kunitomo K, Ooi A, et al. Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immunosorbent assay. Int J Cancer. 2002;98:833-837
23. Tanner M, Hollmén M, Isola J, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005;16:273-278
24. Yano T, Ochiai A, Doi T, et al. Expression of HER2 in gastric cancer: comparison between protein expression and gene amplification using a new commercial kit. J Clin Oncol. 2004;22(14S):4053
25. Risio M, De Rosa G, Chiecchio L, et al. HER2 testing in gastric cancer: molecular morphology and storage time-related changes in archival samples. Int J Oncol. 2003;23:1381-1387
26. Brien TP, Depowski PL, McKenna BJ, et al. Prognostic factors in gastric cancer. Mod Pathol. 1998;11:870-877
27. Ishikawa T, Kobayashi M, Ooi A, et al. Amplification of the c-erbB-2 (HER-2/neu) gene in gastric cancer cells. Detection by fluorescence in situ hybridization. Am J Pathol. 1997;151:761-768
28. Koeppen HK, Wright BD, Hillan KJ, et al. Overexpression of HER2/neu in solid tumours: an immunohistochemical survey. Histopathology. 2001;38:96-104
29. Allgayer H, Babic R, Heiss MM, et al. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol. 2000;18:2201-2209
30. Gürel S, Dolar E, Yerci O, et al. The relationship between c-erbB-2 oncogene expression and clinicopathological factors in gastric cancer. J Int Med Res. 1999;27:74-78
31. Lee KE, Lee HJ, Kim JP, et al. Prognostic signifi-cance of p53, nm23, PCNA and c-erbB-2 in gastric cancer. Jpn J Clin Oncol. 2003;33:173-179
32. Ougolkov A, Yamashita K, Minamoto T, et al. Abnormal expression of E-cadherin, beta-catenin, and c-erbB-2 in advanced gastric cancer: its association with liver metastasis. Int J Colorectal Dis. 2003;18:160-166
33. Sanz-Ortega J, Steinberg SM, Merino MJ, et al. Comparative study of tumor angiogenesis and immunohistochemistry for p53, c-ErbB2, c-myc and EGFr as prognostic factors in gastric cancer. Histol Histopathol. 2000;15:455-462
34. Wang YL, Sheu BS, Chang YC, et al. Overexpression of c-erb-B2 proteins in tumor and non-tumor parts of gastric adenocarcinoma-emphasis on its relation to H. pylori infection and clinicohistological characteristics. Hepatogastroenterology. 2002;49:1172-1176
35. Pinto-de-Sousa J, David L, Pimenta A, et al. C-erbB-2 expression is associated with tumor location and venous invasion and influences survival of patients with gastric carcinoma. Int J Surg Pathol. 2002;10:247-256
36. Shah MA, Kelsen DP. Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease. J Natl Compr Canc Netw. 2010;8:437-447
37. Meza-Junco J, Au HJ, Sawyer MB. Trastuzumab for gastric cancer. Expert Opin Biol Ther. 2009;9:1543-1551
38. Park DI, Yun JW, Sepulveda AR, et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci. 2006;51:1371-1379
39. Van Cutsem E, Ang Y, Bang Y, et al. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). Clin Oncol. 2009;7(18S):LBA4509
40. Nakajima M, Sawada H, Nakano H, et al. The prognostic significance of amplification and overexpression of c-met and c-erbB-2 in human gastric carcinomas. Cancer. 1999;85:1894-1902
41. Zhang XL, Yang YS, Huang J, et al. Comparative study on overexpression of HER2/neu and HER3 in gastric cancer. World J Surg. 2009;33:2112-2118
42. Jørgensen JT. Targeted HER2 treatment in advanced gastric cancer. Oncology. 2010;78:26-33
43. Mizutani T, Onda M, Sugisaki Y, et al. Relationship of C-erbB-2 protein expression and gene amplificationto invasion and metastasis in human gastric cancer. Cancer. 1993;72:2083-2088
44. Hammock L, Lewis M, Cohen C, et al. Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization. Hum Pathol. 2003;34:1043-1047